Siga Technologies (SIGA) Cash from Investing Activities (2010 - 2025)
Siga Technologies' (SIGA) quarterly Cash from Investing Activities came in at -$289576.0 in Q3 2025, down 1191.19% on a YoY basis from $26537.5 in Q3 2024, and down 28957500.0% quarter-over-quarter from -$1.0 in Q2 2025.
Powered by 
Analysis
Siga Technologies (SIGA) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Siga Technologies (SIGA) has reported Cash from Investing Activities for 15 consecutive years, with -$289576.0 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Cash from Investing Activities fell 1191.19% year-over-year to -$289576.0; the trailing twelve-month figure through Sep 2025 stood at -$332308.0 (down 1250.19% YoY), and the FY2024 full-year result was -$42450.0, down 95.75% from the prior year.
- Cash from Investing Activities retreated to -$289576.0 in Q3 2025 per SIGA's latest filing, from -$1.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$1.0 in Q2 2025 and bottomed at -$289576.0 in Q3 2025.
- Historically, Cash from Investing Activities has averaged -$42922.6 across 4 years, with a median of -$19762.0 in 2023.
- The widest YoY moves for Cash from Investing Activities: up 99.95% in 2025, down 1191.19% in 2025.
- Over 4 years, Cash from Investing Activities stood at -$26196.0 in 2021, then climbed by 17.22% to -$21686.0 in 2023, then increased by 17.74% to -$17838.0 in 2024, then plunged by 1523.37% to -$289576.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$289576.0, -$1.0, and -$24893.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 2.11 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -424.26 Mn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | -1.66 Bn |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | -51.79 Mn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 87.50 Mn |
| 10 | Siga Technologies | 235.60 Mn | 80.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -289,576.00 |
| Jun 30, 2025 | -1.00 |
| Mar 31, 2025 | -24,893.00 |
| Dec 31, 2024 | -17,838.00 |
| Sep 30, 2024 | -22,427.00 |
| Jun 30, 2024 | -2,185.00 |
| Jun 30, 2023 | -21,686.00 |
| Dec 31, 2021 | -26,196.00 |
| Jun 30, 2021 | -10,700.00 |
| Mar 31, 2021 | -13,724.00 |
| Mar 31, 2020 | -15,501.00 |
| Dec 31, 2019 | -2.00 |
| Sep 30, 2019 | -20,144.00 |
| Jun 30, 2019 | 3.00 |
| Mar 31, 2019 | -8,951.00 |
| Dec 31, 2018 | 78.26 Mn |
| Jun 30, 2018 | -27,863.00 |
| Dec 31, 2017 | -45,882.00 |
| Sep 30, 2017 | -14,916.00 |
| Jun 30, 2017 | -39,326.00 |